Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe resistance to targeted lung cancer drug

NCT ID NCT06247826

Knowledge-focused Sponsor: Groupe Francais De Pneumo-Cancerologie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why amivantamab, a drug for advanced non-small cell lung cancer with a specific EGFR mutation, stops working over time. Researchers will collect blood and tumor samples from 30 patients when their disease gets worse. The goal is to find genetic changes that cause resistance and help doctors choose better next treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients with advanced NSCLC with EGFR ins20 receiving amivantamab as monotherapy in France under ATU or EAP; * Age ≥ 18 years; * Histologically confirmed advanced NSCLC (metastatic or locally advanced unresectable and not suitable for definitive radiotherapy) with EGFR ins20; * Patients included will be required to sign an informed consent form to collect blood samples (liquid biopsy) and tissue biopsy when available at progression on amivantamab; * Confirmed progression on amivantamab according to RECIST 1.1; * Patient enrolled in the french National Health Insurance program or with a third- party payer. Exclusion Criteria: * Patients receiving amivantamab in combination with another therapy; * Patients who do not consent to liquid biopsy at progression.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR exon 20 insertion mutation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR exon 20 insertion mutation Non-small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Bretagne Atlantique

    RECRUITING

    Vannes, 56017, France

  • CHU Hôpital Nord

    RECRUITING

    Saint-Etienne, 42055, France

  • CHU La Réunion Site Nord

    RECRUITING

    Saint-Denis, 97411, France

  • Centre Hospitalier du Morvan

    RECRUITING

    Brest, 29200, France

  • Hôpital Charles Nicolle

    RECRUITING

    Rouen, 76031, France

  • Hôpital Cochin

    RECRUITING

    Paris, 75014, France

  • Oncologie Institut Curie

    NOT_YET_RECRUITING

    Paris, 75005, France

  • Oncologie Polyclinique Bordeaux Nord Aquitaine

    NOT_YET_RECRUITING

    Bordeaux, 33000, France

  • Oncologie thoracique Hôpital Nord

    RECRUITING

    Marseille, 13915, France

  • Oncologie, CLCC Dijon

    NOT_YET_RECRUITING

    Dijon, 21000, France

  • Oncologie, Centre Antoine Lacassagne

    WITHDRAWN

    Nice, 06149, France

  • Pneumologie CH

    NOT_YET_RECRUITING

    Le Mans, 72000, France

  • Pneumologie CHI Cornouaille

    NOT_YET_RECRUITING

    Quimper, 02900, France

  • Pneumologie Centre Hospitalier

    NOT_YET_RECRUITING

    Pau, 64000, France

  • Pneumologie Centre Hospitalier Intercommunal de Créteil

    RECRUITING

    Créteil, 94010, France

  • Pneumologie, CHU Grenoble

    RECRUITING

    Grenoble, 38043, France

  • Pneumologie, Hôpital Mutualiste Resamut

    NOT_YET_RECRUITING

    Villeurbanne, 69100, France

  • Pneumologie, Hôpital Tenon

    RECRUITING

    Paris, 75970, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.